Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thoratec's joy at LVAD (left ventricular assist device) decision muted by FDA conditions

This article was originally published in Clinica

Executive Summary

Thousands of people in the US who face death each year from congestive heart failure (CHF) could soon have a new treatment at hand, after an FDA advisory panel voted in favour of expanding the use of Thoratec's heart pump for long-term therapy. However, despite Thoratec's delight at the panel's verdict, issues raised by some of the FDA advisors look to have given the company cause for concern.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065089

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel